Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention.
These recommendations update information on the vaccine and antiviral agents available for controlling influenza during the 1996-97 influenza season (superseding MMWR 1995;44(No. RR-3):1-22). The principal changes include information about a) the influenza virus strains included in the trivalent vaccine for 1996-97 and b) extension of the optimal time for influenza vaccination campaigns for persons in high-risk groups.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D000075202:Contraindications; D004347:Drug Interactions; D005260:Female; D006801:Humans; D017589:Immunization Programs; D007115:Immunization Schedule; D007223:Infant; D017053:Infection Control / Q000592:standards; D009980:Influenza A virus / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D007251:Influenza, Human / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D008875:Middle Aged; D011247:Pregnancy; D012299:Rimantadine / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D014481:United States; D014611:Vaccination / Q000009:adverse effects / Q000592:standards*; D015164:Vaccines, Inactivated / Q000008:administration & dosage* / Q000009:adverse effects
D000998:Antiviral Agents; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated; D012299:Rimantadine; D000547:Amantadine